Taureanbull I agree. The ASX has a stigma of being a biotech graveyard especially in a tougher market. I think management have done what they could to expand their horizons and opportunity by partnering with a US pharma and appointing Torreya for overseas scope and market prosperity.
Given that NEU basically just need to repeat the ph2 trials I'm confident we will get the tick for ph3 then regardless of the market manipulation the stock will see a truer value. IMO
GLTA - Patience is the call
Ann: Plans for Phase 3 trial in Rett syndrome, page-37
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1378 | $21.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.29 | 218 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |